Highlight

GR Ligands: Can We Improve the Established Drugs?

  1. Hartmut Rehwinkel Dr.1,
  2. Heike Schäcke Dr.2

Article first published online: 23 MAY 2006

DOI: 10.1002/cmdc.200600070

Issue

ChemMedChem

ChemMedChem

Volume 1, Issue 8, pages 803–805, August 11, 2006

Additional Information

How to Cite

Rehwinkel, H. and Schäcke, H. (2006), GR Ligands: Can We Improve the Established Drugs?. ChemMedChem, 1: 803–805. doi: 10.1002/cmdc.200600070

Author Information

  1. 1

    Schering AG, Corporate Research, Medicinal Chemistry, 13342 Berlin, Germany, Fax: (+49) 30-4689-4841

  2. 2

    Schering AG, Corporate Research, CRBA Inflammation, 13342 Berlin, Germany

Publication History

  1. Issue published online: 3 AUG 2006
  2. Article first published online: 23 MAY 2006
  3. Manuscript Received: 15 MAR 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (75K)

Keywords:

  • glucocorticoids;
  • immunology;
  • inflammation;
  • receptors;
  • transcription
Thumbnail image of graphical abstract

Glucocorticoids (GCs) represent the most effective therapy for acute and chronic inflammatory disorders, yet they can elicit severe side effects. New classes of GC receptor ligands appear to have all of the benefits and fewer side effects and have prompted new research into an old drug target. Compound A (shown) is the latest addition to this exciting development.

View Full Article (HTML) Get PDF (75K)